|
|
| A Full-Service Outsourcing Partner With 97% Customer Retention | inSeption Group offers a full-service solution designed to disrupt the current outsourcing paradigm, resurrecting a common-sense approach to rebuild business trust and confidence in a client’s selected vendor. Primarily focused on oncology, hematology, neurodegenerative disorders, and rare/orphan disease indications, with a specialization in cell and gene therapy, inSeption has been a solution for its' clients who have experienced the progressive degradation of today’s outsourcing options. Contact them. |
|
|
|
|
OSE Immunotherapeutics is poised to begin a confirmatory and pivotal Phase 3 trial for a novel cancer vaccine targeting the second line in NSCLC, an area of acute unmet need. |
|
|
|
|
|
|
|
|
| A Model For Improving TMF Management | Get pragmatic details of what it took to build a successful partnership, why it has become a model for other departments within Regeneron, and lessons learned you can apply in your organization. |
|
|
|
|
CONTRIBUTE TO LIFE SCIENCE LEADER |
|
|
|
Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director. |
|
|
Connect With Life Science Leader: |
|
|
|